2018, Healthcare Provider, Patients and Pharmacology

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

2018

Healthcare Provider

Patients

Pharmacology

The potential of virtual reality-based therapy for serious mental disorders

Pharmaceutical Technology

AUGUST 12, 2022

The FDA’s breakthrough device programme is for medical devices or device-led combination products that provide more effective treatment or diagnosis of diseases. The aim of the programme is to expedite the development, assessment and review of medical devices in order to provide timely access to patients and healthcare providers.

Food and Drug Administration

Food and Drug Administration Pharmacology Side effects Physicians

Understanding a rare disease through the lens of real world and prevalence data

Clarivate

FEBRUARY 28, 2023

LHON mutation rate variability affects therapeutic efficacy Most LHON patients carry one of three pathogenic mitochondrial DNA mutations (11778G>A [ND4], 14484T>C [ND6] and 3460G>A [ND1]) known as primary LHON mutations. We identified patients with an LHON diagnosis using ICD-10 and ICD-9 codes H47.2 The Clarivate U.S.

Prescription

Prescription Patients Pharmacology Healthcare

Pharma Rep Focus

The potential of virtual reality-based therapy for serious mental disorders

Understanding a rare disease through the lens of real world and prevalence data

Stay Connected